Soligenix (SNGX) vs Theriva Biologics (TOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Theriva Biologics is the larger company by market cap ($5.5 million vs $5.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SNGX | TOVX |
|---|---|---|
| Share price | $0.2201 | $0.12 |
| Market cap | $5.14M | $5.51M |
| 1-day change | -8.29% | -6.25% |
| YTD return | — | -42.86% |
| 1-year return | — | -45.45% |
| 5-year return | — | -99.86% |
| P/E ratio (TTM) | — | 0.10 |
| EPS (TTM) | $-0.21 | $1.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-11.08M | $-23.74M |
| 52-week high | $1.70 | $0.49 |
| 52-week low | $0.21 | $0.12 |
| Distance from 52-week high | -87.05% | -75.51% |
| Analyst consensus | none | none |
| Avg. price target upside | +526.99% | +1983.33% |
| Average volume | 198.15K | 2.02M |
| Shares outstanding | 23.37M | 45.89M |
| Employees | 13 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Soligenix
SNGX stock →Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
SNGX vs TOVX FAQ
Which is bigger, Soligenix or Theriva Biologics?
Theriva Biologics (TOVX) is larger, with a market capitalization of $5.51M compared with $5.14M for Soligenix (SNGX).
Are Soligenix and Theriva Biologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.